ArticleScientific reports2024
A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.Preventive medicine reports · 2026Article
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.Oncotarget · 2026Article
- Synchronous Multiple Primary Tumors in a Dog: A Case Report.Case reports in veterinary medicine · 2026Article
- Synchronous uterine leiomyosarcoma and pulmonary adenocarcinoma in a meerkat (Suricata suricatta): a case report.BMC veterinary research · 2025Article
- Clinical and genetic features of multiple primary tumours cohorts with a renal cell carcinoma: Implications for molecular genetic investigations.International journal of cancer · 2025Article
- Synchronous Versus Metachronous Multiple Malignant Tumors Involving the Digestive Tract: Predictors of Survival from a Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- The risk of mortality from multiple primary cancers in colorectal cancer survivors: analysis of data from the South Australian Cancer Registry.Journal of cancer research and clinical oncology · 2025Article
- A Case Report of Multiple Primary Malignancies Presenting With Unusual Inguinal Metastasis.Cureus · 2025Article
- [Diagnostic approaches and clinical relevance of hereditary hematological malignancies].Magyar onkologia · 2025Review
- A Rare Case of Synchronous Multiple Primary Malignancies of the Pancreas, Skin, and Thyroid.Case reports in oncological medicine · 2025Article
- Lung adenocarcinoma and colorectal cancer as double primary malignancies reveal lynch syndrome: a case report of germline MLH1 mutation with response to immunotherapy and familial aggregation.Frontiers in immunology · 2025Article
- Genotoxic and Anti-Genotoxic Assessments of FermentedFoods (Basel, Switzerland) · 2024Article
- Tumour mutation burden and infiltrating immune cell subtypes influenced the breast cancer prognosis.Translational cancer research · 2024Article
- Case report: Long-term response to a combination of immune checkpoint inhibitors as a single treatment for multiple synchronous cancers: a case study.Frontiers in immunology · 2024Article
- Preparing for the Era of Multiple Primary Cancers: A Prevention-Centered Model for Survivorship Medicine.Technology in cancer research & treatmentArticle
- Integrated transcriptomic and immunogenomic analysis unravels the immunological functions and prognostic landscape of WD repeat domain 76.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Multiple primary cancer (MPC) denotes individuals with two or more malignant tumors occurring simultaneously or successively. Herein, a total of 11,000 pancancer patients in TCGA database (1993-2013) were divided into MPC or non-MPC groups based on their history of other malignant tumors. The incidence of MPC has risen to 8.5-13.1% since 2000. Elderly individuals, males, early-stage cancer patients, and African Americans and Caucasians are identified as independent risk factors (p < 0.0001). Non-MPC patients exhibit significantly longer overall survival (OS) and disease-free survival (DFS) (p = 0.0038 and p = 0.0014). Age (p < 0.001) and tumor staging at initial diagnosis (p < 0.001) contribute to this difference. In our center, MPC was identified in 380 out of 801 tumor events based on SEER criteria. The peak occurrence of secondary primary was about 1-5 years after the first primary tumor, with a second small peak around 10-15 years. Multiple tumors commonly occur in the same organ (e.g., breast and lung), constituting 12.6%. Certain cancer types, notably skin cutaneous melanoma (SKCM), exhibit significantly higher tumor mutational burden (TMB) in the MPC group (17.31 vs. 6.55 mutations/MB, p < 0.001), with high TMB associated with improved survival (p < 0.001). High TMB in MPC may serve as a predictor for potential immunotherapy application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.